Prednisolon EQL Pharma now approved for sale

The drug Prednisolon EQL Pharma has now been approved for sale by the Swedish Medicines Agency.

Prednisolone EQL Pharma is used in the state where one needs to suppress the body's reaction such as the inflammatory response in rheumatoid arthritis (RA). Other examples mentioned include connective tissue disease (SLE), vessel wall inflammation, connective tissue changes, asthma, colitis colitis, certain blood disorders, severe allergic conditions and tumor therapy.

In the Nordic region, the Swedish market is the largest with about 25 million SEK in annual sales. There are only a few competitors in the Nordic region in accordance with EQL Pharmas long-term strategy.

The product is expected to be launched in the second half of 2018.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

About EQL Pharma 

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets eight (8) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.